Business Standard

Tata group to launch India's first low-cost Covid-19 test 'Feluda'

This test uses an indigenously developed, cutting-edge CRISPR technology for detection of the genomic sequence of SARS-CoV-2 virus

Coronavirus, mask
Premium

The Tata CRISPR test achieves accuracy levels of traditional RT-PCR tests with quicker turnaround time, less expensive equipment and better ease of use

Press Trust of India
The Drugs Controller General of India has approved of the commercial launch of ‘Feluda’, the Tata CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) Covid-19 test, the Council of Scientific and Industrial Research (CSIR) said recently.

This test uses an indigenously developed, cutting-edge CRISPR technology for detection of the genomic sequence of SARS-CoV-2 virus, CSIR said in a statement.
 
The Tata CRISPR test achieves accuracy levels of traditional RT-PCR tests with quicker turnaround time, less expensive equipment and better ease of use. CRISPR is a genome editing technology to diagnose diseases.

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Sep 21 2020 | 12:43 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com